ZA9303926B - Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules - Google Patents

Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules

Info

Publication number
ZA9303926B
ZA9303926B ZA9303926A ZA9303926A ZA9303926B ZA 9303926 B ZA9303926 B ZA 9303926B ZA 9303926 A ZA9303926 A ZA 9303926A ZA 9303926 A ZA9303926 A ZA 9303926A ZA 9303926 B ZA9303926 B ZA 9303926B
Authority
ZA
South Africa
Prior art keywords
blomolecules
conjuction
polyoxymethylene
oxyethylene copolymers
oxyethylene
Prior art date
Application number
ZA9303926A
Inventor
Colin G Pitt
Wayne Hendren
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US90003792A priority Critical
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA9303926B publication Critical patent/ZA9303926B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
ZA9303926A 1992-06-17 1993-06-04 Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules ZA9303926B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US90003792A true 1992-06-17 1992-06-17

Publications (1)

Publication Number Publication Date
ZA9303926B true ZA9303926B (en) 1994-01-03

Family

ID=25411886

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9303926A ZA9303926B (en) 1992-06-17 1993-06-04 Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules

Country Status (10)

Country Link
US (1) US5476653A (en)
EP (1) EP0576192A3 (en)
JP (1) JPH07508727A (en)
CN (1) CN1083822A (en)
AU (1) AU4538993A (en)
CA (1) CA2138277A1 (en)
IL (1) IL105918D0 (en)
MX (1) MX9303601A (en)
WO (1) WO1993025212A1 (en)
ZA (1) ZA9303926B (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867181B1 (en) 1997-06-02 2005-03-15 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
IL110787D0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
IL112583D0 (en) * 1994-02-08 1995-05-26 Amgen Inc Oral delivery of chemically modified proteins
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active agent, a polyether, and optionally, a non regarded as foreign, native protein
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20050158273A1 (en) * 1997-09-25 2005-07-21 Harris J. M. Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US8614291B2 (en) * 1999-08-10 2013-12-24 Poly-Med, Inc. Phosphorylated polymers and conjugates thereof
CA2345138C (en) * 1998-10-16 2009-12-15 Biogen, Inc. Polymer conjugates of interferon beta-1a and their uses
HU0200414A2 (en) * 1998-10-16 2002-06-29 Biogen Inc Interferon-betha fusion proteins and uses
DE10082068C5 (en) * 1999-07-01 2009-02-05 Asahi Kasei Kabushiki Kaisha Low molecular weight oxymethylene polymer and composition containing this polymer and method of preparation
DE19936715A1 (en) * 1999-08-06 2001-02-15 Ticona Gmbh Low-emission colored polyoxymethylene molding compositions
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
NZ520261A (en) 2000-01-10 2003-10-31 Maxygen Holdings Ltd Granulocyte colony-stimulating factor PEG conjugates that exhibit an increased bioavailability and half-life in vivo and reduced side effects and immunogenicity
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
BR0211071A (en) * 2001-07-11 2004-12-21 Maxygen Holdings Ltd Polypeptide conjugate exhibiting G-CSF activity, a method for preparing a G-CSF conjugate, composition, method for treating a mammal suffering from an insufficient neutrophil level, and use of polypeptide conjugate
AT428445T (en) 2000-02-11 2009-05-15 Bayer Healthcare Llc Cleaning factor vii or viia conjugate
SK11882003A3 (en) 2001-02-27 2004-03-02 Maxygen Aps New interferon beta-like molecules
CA2450985A1 (en) * 2001-06-28 2003-01-09 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
WO2003033539A1 (en) * 2001-10-16 2003-04-24 Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Rossiiskoi Akademii Nauk Composition for polymerising immobilisation of biological molecules and method for producing said composition
RS55578B1 (en) 2002-01-18 2017-06-30 Biogen Ma Inc Polyalkylene polymer compounds and uses thereof
EP1585817B1 (en) 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
BR0311978A (en) 2002-06-21 2005-03-22 Novo Nordisk Healthcare Ag Preparation, method for preparing it, pharmaceutical formulation, methods for treating a factor responsive syndrome vii, to prevent unwanted bleeding, to prevent unwanted blood clotting and to prevent tissue factor mediated reactions, and to use a preparation
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1667708B9 (en) 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
KR101162908B1 (en) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EP1624883A4 (en) * 2003-04-09 2008-11-26 Univ Utah Res Found Compositions and methods related to production of erythropoietin
AT481420T (en) 2003-10-10 2010-10-15 Novo Nordisk As Il-21 derivatives
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
EP1696947B1 (en) 2003-12-19 2014-02-26 F.Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
AU2005327906B2 (en) 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AT542920T (en) 2004-12-22 2012-02-15 Ambrx Inc Modified human growth hormone
BRPI0518661A2 (en) 2004-12-22 2008-12-02 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
MX2007007581A (en) * 2004-12-22 2007-07-24 Ambrx Inc Compositions of aminoacyl-trna synthetase and uses thereof.
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
JP2008535610A (en) 2005-04-15 2008-09-04 インターフェース バイオロジクス インコーポレーティッド Methods and compositions for delivering biologically active agents
US7381805B2 (en) * 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
AU2005335491B2 (en) * 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
WO2007056448A2 (en) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
KR20080079643A (en) * 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 Methods and compositions comprising non-natural amino acids
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2008010841A (en) * 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Segmented degradable polymers and conjugates made therefrom.
EP2029738A2 (en) 2006-05-24 2009-03-04 Novo Nordisk Health Care AG Factor ix analogues having prolonged in vivo half life
MX2009002460A (en) * 2006-09-08 2009-03-20 Ambrx Inc Hybrid suppressor trna for vertebrate cells.
MX2009002526A (en) * 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2008137471A2 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX338336B (en) * 2007-11-20 2016-04-07 Ambrx Inc Modified insulin polypeptides and their uses.
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptides and uses thereof
AU2009274076C1 (en) 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
BRPI0919403A2 (en) 2008-09-26 2017-09-26 Ambrx Inc modified animal erythropoietin polypeptides and their uses
JP5709754B2 (en) 2008-09-26 2015-04-30 アンブルックス,インコーポレイテッドAmbrx,Inc. Microorganisms and vaccines that rely on replication with unnatural amino acids
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
MX349301B (en) 2009-12-21 2017-07-21 Ambrx Inc Modified bovine somatotropin polypeptides and their uses.
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
JP2013528374A (en) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Polypeptide inhibitors of VLA4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522A8 (en) 2010-08-17 2017-12-26 Ambrx Inc "modified relaxin polypeptides comprising a non-naturally encoded amino acid, use, method of preparation as well as nucleic acid encoding them"
BR112014000055A2 (en) 2011-07-01 2017-06-13 Bayer Ip Gmbh relaxin fusion polypeptides and uses thereof
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US8779070B2 (en) 2012-07-31 2014-07-15 Empire Technology Development Llc Alkyl ether compositions and methods of use
WO2014021844A1 (en) * 2012-07-31 2014-02-06 Empire Technology Development Llc Alkyl ether compositions and methods of use
SI2890402T1 (en) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298A1 (en) 2013-10-11 2016-08-17 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN110078814A (en) 2014-10-24 2019-08-02 百时美施贵宝公司 FGF-21 polypeptide of modification and application thereof
KR20190115049A (en) 2017-02-08 2019-10-10 브리스톨-마이어스 스큅 컴퍼니 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
KR0146285B1 (en) * 1989-08-09 1998-08-17 마에다 가쓰노스께 Polyoxymethylene multi copolymer and its resin composition
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69230372T2 (en) * 1991-03-19 2000-06-15 Cytrx Corp Polyoxypropylene / polyoxyethylene copolymers with improved biological activity

Also Published As

Publication number Publication date
AU4538993A (en) 1994-01-04
WO1993025212A1 (en) 1993-12-23
MX9303601A (en) 1994-06-30
EP0576192A2 (en) 1993-12-29
JPH07508727A (en) 1995-09-28
EP0576192A3 (en) 1994-05-18
IL105918D0 (en) 1993-10-20
US5476653A (en) 1995-12-19
CA2138277A1 (en) 1993-12-23
CN1083822A (en) 1994-03-16

Similar Documents

Publication Publication Date Title
AU667789B2 (en) Improvements in injection devices
DE59407692D1 (en) Brenner
DE69405102D1 (en) Antikoerperfragmente in therapie
DE69425556D1 (en) Äthylen copolymerisation
GB9200388D0 (en) Improvements in or relating to contrast agents
HU9402565D0 (en) Improvements in or relating to contrast agents
GB9200387D0 (en) Improvements in or relating to contrast agents
HK1003293A1 (en) Improvements in or relating to contrast agents
SG46373A1 (en) Improvements in or relating to contrast agents
IL111316A (en) Injection device
HU9600932D0 (en) In-alkyl-n-arylpyrimidinamines and derivatives thereof
GB9306887D0 (en) Random block copolymers
LU91117I2 (en) Cetuximab in combination with irinotecan.
DE69229231D1 (en) In containern transportierte feldküche
IE873388L (en) Terephthalate ester copolymers and their use in laundry¹compositions.
NZ241613A (en) Highlighting intagliations in tablets
EP0659768A3 (en) Antigen-carbohydrate conjugates and their use in immunotherapy.
EP0658116A4 (en) Methods useful in endotoxin prophylaxis and therapy.
IL99081D0 (en) Oxime-carbamates and oxime-carbonates
GB9306729D0 (en) Improvements in separators
GB8816667D0 (en) Improvements in pollution control
IE892293L (en) Pyrrolidinyl-3-quinolone and naphthyridone- carboxylic acid¹derivatives
IL107081A (en) Azaquinoxalines and their use
EP0354403A3 (en) Load-supporting device
IL91857D0 (en) Linear interpolymer blends